BioSpace News Archive

Funding supports efforts by National Organization for Rare Disorders (NORDⓇ) and Global Genes to address needs of the rare disease community arising from COVID-19 pandemic

Cellics Therapeutics, Inc. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters , entitled Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity, based on research conducted by its founder, Liangfang Zhang, Ph.D. http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c02278 As new informa

The NAVC’s VMX Virtual platform uses advanced simulation technology to virtually recreate a 3D, lifelike experience allowing job seekers to connect with hiring organizations, including Banfield Pet Hospital®, Petco and VCA Animal Hospitals among others

Ubiquigent Limited (Ubiquigent) today announced the continuation of a collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise. The central role of ubiquitylation in diverse cellular processes, including pr

96% Mean Reduction in Factor VIII Usage Greater than 90% Reduction in Bleeding Episodes, Cumulative Mean Annualized Bleeding Rates Remain Less than One (1) Webinar with BioMarin Management and Study Investigators, Professor John Pasi and Dr. Steve Pipe Today at 5:00 PM ET [17-June-2020] SAN RAFAEL, Calif. , June 17, 2020 /PRNewswire/ -- BioMarin Ph

Developing and Manufacturing Novel RNAi drug Candidates Using Precision NanoSystems’ NxGen™ Platform

Units Offer Hands-On Education Around All Treatment Modalities Including Home Dialysis for Patients Recently Diagnosed with Kidney Failure

ALK gains exclusive rights to market OTIPRIO in U.S. for acute otitis externa including to ear, nose and throat (ENT) physicians, pediatricians and select primary care physicians

State-of-the-art lab and office space is home to biotech companies that have raised more than $31 million

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell , PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus’ progress and host one-on-one meetings with investo